| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8656999 | Atherosclerosis | 2018 | 8 Pages |
Abstract
PPARGC1B and CNTN4 genotypes are associated with elevated thromboxane A2 formation and with an excess of cardiovascular events. Aspirin appears to blunt these associations. If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is confirmed by additional studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision making regarding the use of aspirin in primary prevention.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Nina S. McCarthy, Ciara Vangjeli, Praveen Surendran, Achim Treumann, Cathy Rooney, Emily Ho, Peter Sever, Simon Thom, Alun D. Hughes, Patricia B. Munroe, Philip Howard, Toby Johnson, Mark Caulfield, Denis C. Shields, Eoin O'Brien, Desmond J. Fitzgerald,